Oncology Center of Excellence (OCE) Drug Labelling Initiative
Closed Solicitation Posted
This opportunity was awarded. See the award notice from .
- Solicitation number
- FDA-RFP-1227793
- Agency
-
FDA Office of Acquisition and Grant Services
Food and Drug Administration, Department of Health and Human Services
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 541611 Administrative Management and General Management Consulting Services
- Place of performance
- Silver Spring MD 20993 USA
Notice details come from SAM.gov. Updated .
About this opportunity
The Food and Drug Administration seeks proposals to establish operations and deploy an iterative labeling evidence evaluation process to support the Oncology Center of Excellence Drug Labeling Initiative. Offerors must provide all necessary facilities, materials, personnel and services to automate data collection, develop documentation, conduct communications and stakeholder engagement activities, and provide publication and presentation support. Proposals will be evaluated on the basis of technical approach, management approach, past performance and price. The closing date for proposals is July 29, 2020, with questions due by July 6.
There is no set-aside designated for this requirement. Performance will take place in Silver Spring, Maryland. The contract type will be time and materials over a one year base period and a one year option period. Offerors are required to propose fully burdened commercial labor rates by category. The solicitation seeks to analyze the labeling of up to six specific oncology drugs to gather user feedback, collect prescription data, and make recommendations to FDA for potential label updates.
Notice text
2 versions
Update #2 · Latest ·
Amendment 1 to FDA solicitation number: FDA-RFP-1227793
The purpose of this Amendment 1 to FDA-RFP-1227793 is to provide responses to vendor questions received before the questions submission deadline stated in the solicitation. This Amendment 1 also includes revisions to the solicitation which are highlighted in yellow in the solicitation document. Please also note the revised bid submission deadline. Please refer to the attached amendment and FDA responses document for specific information.
Update #1 ·
FDA solicitation number: FDA-RFP-1227793
This is a combined synopsis/solicitation for commercial services and program support for a requirement entitled, "Oncology Center of Excellence (OCE) Drug Labelling Initiative". Please refer to the attached Request for Proposal for specific information.
Files
| File | Type | Posted |
|---|---|---|
| Sol Doc_1227793_Amendment 1.pdf | ||
| FDA-RFP-1227793_A1_FDA Responses.pdf | ||
| FDA-RFP-1227793_Attachment 1 - RFP Questions Template.docx | DOCX document | |
| Sol Doc_1227793.pdf |
Notice history
| Notice | Type | Posted |
|---|---|---|
| Oncology Center of Excellence (OCE) Drug Labelling Initiative | Award Notice | |
| This notice | Solicitation |
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| FDA/CDRH Scientific Technical Capacity for Regulatory Review | FDA Office of Acquisition and Grant Services | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity